Market Overview

Glancy Prongay & Murray LLP Continues Investigation on Behalf of Mednax, Inc. Investors (MD)

Share:

Glancy
Prongay & Murray LLP
("GPM") continues its investigation on
behalf of Mednax, Inc. ("Mednax" or the "Company") (NYSE: MD)
investors concerning the Company and its officers' possible violations
of federal securities laws.

If you are a shareholder who suffered a loss, click here
to participate.

On April 20, 2017, Mednax announced poor financial results for the first
quarter of 2017, including missed earnings. Mednax also reported that
"[s]ame-unit revenue from net reimbursement-related factors is expected
to decline by 0.6 percent for the first quarter of 2017, compared to the
first quarter of 2016, driven by a 90 basis point payor mix shift to
government payors that impacted same-unit pricing negatively by 150
basis points." On this news, Mednax's share price fell $5.39, or 8.1%,
to close at $61.30 per share on April 20, 2017.

Then, on July 28, 2017, during its second quarter earnings call, Mednax
announced that the Company had failed to complete acquisitions of
anesthesiologist practices during the quarter and that any future
anesthesiologist acquisitions were unlikely, citing the "challenging"
payor mix combined with "continued … growth in compensation expense for
nurse anesthetists." On this news, Mednax's share price fell $8.76 or
15.5%, to close at $47.73 per share on July 28, 2017, thereby further
injuring investors.

Follow us for updates on Twitter: twitter.com/GPM_LLP.

If you purchased Mednax securities, have information or would like to
learn more about these claims, or have any questions concerning this
announcement or your rights or interests with respect to these matters,
please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East,
Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at
888-773-9224, by email to shareholders@glancylaw.com,
or visit our website at www.glancylaw.com.
If you inquire by email please include your mailing address, telephone
number and number of shares purchased.

This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.

View Comments and Join the Discussion!